Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Amprenavir:ACnc:Pt:Ser/Plas:Qn

Known as: ????:?????:???:??/??:???, amprenavir:concentración arbitraria:punto en el tiempo:suero/plasma:cuantitativo, Amprenavir:Arbitraire concentratie:Moment:Serum of plasma:Kwantitatief 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Amprenavir is an HIV-1 protease inhibitor, the first in vitro activity studies of which were published in 1995. During in vivo… Expand
  • table II
  • figure 1
  • table IV
  • table V
  • table VI
2012
2012
A series of P1-substituted biaryl amprenavir derivatives was designed and synthesized. These compounds were evaluated for enzyme… Expand
  • figure 1
  • table 1
  • figure 2
2007
2007
OBJECTIVES The purpose of this study was to evaluate the steady-state pharmacokinetics of amprenavir and ritonavir in HIV… Expand
Review
2007
Review
2007
BACKGROUND Emerging evidence suggests that female sex may be associated with increased risk of developing antiretroviral… Expand
2003
2003
ABSTRACT The protease inhibitor (PI) ritonavir is used as a strong inhibitor of cytochrome P450 3A4, which boosts the activities… Expand
2002
2002
Starting from the chemical structure of the recent FDA-approved anti-HIV drug Amprenavir (Agenerase), a potent HIV-protease… Expand
2002
2002
ABSTRACT In this crossover study in 12 healthy volunteers, coadministration of amprenavir (1,200 mg; single dose) with grapefruit… Expand
Highly Cited
2001
Highly Cited
2001
ABSTRACT In a dose-ranging study of amprenavir (formerly 141W94), an inhibitor of the protease enzyme of human immunodeficiency… Expand
Review
2000
Review
2000
UNLABELLED The virological/immunological efficacy of amprenavir-containing combination regimens has been evaluated in a small… Expand
  • figure 1
  • table I
  • table II
  • figure 2
  • table III